Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease

Phase 4 Completed 23 enrolled University of South Florida

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will assess the effectiveness of solifenacin succinate (VESIcare) in reducing symptoms of overactive bladder in Parkinson's disease (PD) patients.

Timeline

Start: 2010-01
Primary completion: 2014-08
Completion: 2014-08

Outcome

Missed primary endpoint

registry analysis (unspecified test); Solifenacin Succinate (VESIcare) vs Placebo; p = 0.53; Effect size 0.20; ANCOVA NCT01018264 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Solifenacin	Small molecule	10 mg	Oral

Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease

Summary

Timeline

Outcome

Drugs

Indications